Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil.
about
Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy.Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.Early ileocolonoscopy with biopsy for the evaluation of persistent post-transplantation diarrheaSafety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation.Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry.Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection.UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients.Association of mycophenolic acid dose with efficacy and safety events in kidney transplant patients receiving tacrolimus: an analysis of the Mycophenolic acid Observational REnal transplant registry.Novel methods for tracking long-term maintenance immunosuppression regimens.A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients.The first year post-heart transplantation: use of immunosuppressive drugs and early complications.Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors.Enteric-coated mycophenolate sodium: an update.Diarrhea caused by viruses in transplant recipients.Validation of the cell line LS180 as a model for study of the gastrointestinal toxicity of mycophenolic acid.Gastrointestinal complications in renal transplant recipients detected by endoscopic biopsies in a developing country.Enteric-coated mycophenolate sodium - current and future use in transplant patients.Routine prophylaxis with proton pump inhibitors and post-transplant complications in kidney transplant recipients undergoing early corticosteroid withdrawal.Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.The Immunosuppressant Mycophenolic Acid Alters Nucleotide and Lipid Metabolism in an Intestinal Cell Model.Conversion to enteric-coated mycophenolate sodium from mycophenolate mofetil in stable renal transplant patients: results of an Asia-Pacific study.Enteric-coated mycophenolate sodium.Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study.Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium.Adverse symptoms of immunosuppressants: A survey of Canadian transplant clinicians.Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats.
P2860
Q31047067-4D5F2244-DF66-411F-A551-4B0F0B6DDD20Q33408239-10A093F3-4763-45CD-8391-6EDBBB85E138Q34063731-CCA93C0B-F753-42F6-B4DF-CF6B0122CD93Q34339626-B60FC976-FFCC-4CFA-A789-DE03D8DC62A2Q34365272-83CDB213-A8DA-45EF-ABE9-47D447DB199CQ34607590-4C6C5F4E-FB1C-48D1-B232-83398A209199Q34947658-3C514D8A-E774-404C-B9F6-C19E5BE89DB5Q36566866-54CDA535-3B26-4DD9-A1DA-958D524320A6Q36666963-1A4B278D-DCED-427B-BE11-B6CC53D432DBQ36941933-E4797EF3-81DF-480C-98B5-4E652471F388Q37089563-2EB330E8-15A2-448B-AC5D-9ECBAF7B263FQ37838123-FB01BA58-2C33-4E0B-AAD8-A638FEC852B0Q38027466-227644CB-F35C-4CDF-B6FA-599E5C46D22DQ38199765-DDACD2B6-C1D5-48D4-8D87-3398F936D761Q38205920-EC4D5D8F-3A2A-446A-BD72-9BFC70FFE411Q38704055-A37184D0-C061-42C9-833E-B85F6F63B44BQ39095599-22F8975A-5097-40D9-AD5B-BADCC63F5CE4Q40409829-B63CF034-837D-4974-9549-58E3E7C29687Q40744956-284B7B80-E2CE-4A37-B3A9-54B39AF97ABDQ41107370-15870192-E540-48C3-9F89-2086B02DD9F2Q41768816-5329EDA8-A582-4837-908D-CB99AF93C543Q42674826-FD7C86C3-85B0-4DFC-8D0F-1CB9047470DBQ42925114-F45045D8-0F04-45D8-B3B1-CB15B5C535F9Q46304002-7040A2C3-7A5F-4794-B5E6-F99901B7B1AEQ46620913-2CFD6E7F-7C0A-42FB-9CAC-E258328BBBA9Q47759755-CDB6BB6F-0EDE-4B52-8909-F99EDD9719FDQ55518653-CB1CADAE-6FE4-4625-904C-7C543776FB6F
P2860
Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Long-term outcome of gastroint ...... ed with mycophenolate mofetil.
@en
type
label
Long-term outcome of gastroint ...... ed with mycophenolate mofetil.
@en
prefLabel
Long-term outcome of gastroint ...... ed with mycophenolate mofetil.
@en
P2093
P2860
P1476
Long-term outcome of gastroint ...... ed with mycophenolate mofetil.
@en
P2093
Daniel C Brennan
Jeffrey Lowell
Karen L Hardinger
Mark A Schnitzler
P2860
P304
P356
10.1111/J.1432-2277.2004.TB00394.X
P577
2004-10-29T00:00:00Z